Taro Announces Resignation of Chief Financial Officer
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) has announced the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021. Ms. Huang is leaving to explore other opportunities. The CEO, Uday Baldota, expressed gratitude for her contributions, particularly during the COVID-19 pandemic. The company is now in the process of searching for her successor.
Taro remains committed to its mission of developing high-quality healthcare products.
- Transition period may bring new leadership perspectives.
- Potential for fresh strategies in financial management.
- Loss of experienced CFO may create continuity concerns.
- Possible experience gap during transition period.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021. Ms. Huang is leaving the Company in order to pursue other opportunities.
Mr. Uday Baldota, Taro’s CEO, stated, “On behalf of the Company, I want to thank Daphne for her valuable contributions including her efforts over the past year during the COVID-19 pandemic. We wish her the best in her future endeavors.”
The Company has initiated a search for a successor as Chief Financial Officer.
About Taro
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005916/en/
FAQ
What date did Taro's CFO resign?
Why did Daphne Huang resign from Taro?
Who is looking for a new CFO at Taro?
What impact might the CFO resignation have on TARO stock?
